Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Antipsychotic drug is the mainstay of treatment for schizophrenia, and there are large inter-individual differences in clinical response and side effects. Pharmacogenetics provides a valuable tool to fulfill the promise of personalized medicine by tailoring treatment based on one's genetic markers. AREAS COVERED IN THIS REVIEW: This article reviews the pharmacogenetic literature from early 1990s to 2010, focusing on two aspects of drug action: pharmacokinetics and pharmacodynamics. Genetic variants in the neurotransmitter receptors including dopamine and 5-HT and metabolic pathways of drugs including CYP2D6 and COMT were discussed in association with clinical drug response and side effects. WHAT THE READER WILL GAIN: Readers are expected to learn the up-to-date evidence in pharmacogenetic research and to gain familiarity to the issues and challenges facing the field. TAKE HOME MESSAGE: Pharmacogenetic research of antipsychotic drugs is both promising and challenging. There is consistent evidence that some genetic variants can affect clinical response and side effects. However, more studies that are designed specifically to test pharmacogenetic hypotheses are clearly needed to advance the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 4×
“5 HTR2C Most SGAs except quetiapine tightly bind to 5-HT 2C receptors, in addition to the 2A receptors [5].”
InfluentialSachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638 · cited 2×
“Blockage of D2 receptors in the striatum is believed to be ‘necessary and sufficient’ in achieving antipsychotic effects [4], at least for positive symptoms, although D3, D4 receptors and 5-HT as well as the glutamate system may also be involved in drug action [5].”
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450 · cited 1×
“Recent meta-analyses of the relationship between the polymorphism and antidepressant response have shown that patients carrying the long allele are about twice as likely to respond to treatment at 4 weeks and reach remission, and less likely to suffer from side effects than patients with the short/short genotype [51].”
Genomewide Association Studies: History, Rationale, and Prospects for Psychiatric Disorders
Psychiatric GWAS Consortium Coordinating Committee (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08091354 · Cited by 450
Barnett, J. H., Scoriels, L., & Munafò, M. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.005 · Cited by 412
Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects
Åberg, K., Adkins, D. E., Bukszár, J., Webb, B. T., Caroff, S. N., Miller, D. D., Sebat, J., Stroup, S., Fanous, A. H., Vladimirov, V. I., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.036 · Cited by 130 · cited 2×
“Up-to-date, there have been six GWAS studies of antipsychotic drugs published, four from the CATIE trial [103-106] and two from Volpi’s group [107,108].”
Cited by
From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways
Rogers, G. B., Keating, D. J., Young, R. L., Wong, M.-L., Licinio, J., & Wesselingh, S. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.50 · Cited by 969
Nikolac Perkovic, M., Nedic Erjavec, G., Zivkovic, M., Sagud, M., Uzun, S., Mihaljevic-Peles, A., Kozumplik, O., Muck-Seler, D., & Pivac, N. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3515-4 · Cited by 35
Metadata
- Authors
- Zhang, J.-P., & Malhotra, A. K.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2010-12-22
- Volume
- 7
- Issue
- 1
- Pages
- 9-37
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2010425739
- Cited by
- 195
- References
- 11
- FWCI
- 16.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. https://app.cochat.ai/papers/10.1517/17425255.2011.532787
- The paper
- Zhang, J.-P., & Malhotra, A. K. (2011). Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2011.532787
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.